Inhaled RNA Strategy Remodels Tumor Collagen for Lung Cancer Immunotherapy

Study Background and Research Question

Lung cancer remains a leading cause of cancer-related mortality, in part due to the limited effectiveness of immunotherapies when confronted by the hostile tumor microenvironment (TME). The TME is characterized by dense extracellular matrix (ECM) components, particularly aligned collagen fibers, which act as both physical and immunological barriers. These structures not only restrict the infiltration of cytotoxic T cells but also facilitate immune evasion mechanisms, such as upregulation of PD-L1 on tumor cells. Overcoming these barriers is central to improving the efficacy of cancer immunotherapies. The reference study (Hu et al., 2025) set out to address two intertwined challenges: disrupting the ECM-driven immune exclusion and simultaneously suppressing immune checkpoint-mediated immunosuppression in lung cancer.

Key Innovation from the Reference Study

The study introduces a dual-action, inhalable lipid nanoparticle (LNP) platform designed to deliver RNA therapeutics directly to the lung tumor site. The innovation lies in the simultaneous delivery of:

• mRNA encoding anti-DDR1 single-chain variable fragments (scFv): These antibody fragments are secreted by transfected cells and block the interaction between DDR1 and collagen, disrupting collagen fiber alignment and reducing ECM-mediated T cell exclusion.
• siRNA targeting PD-L1 (siPD-L1): Silencing PD-L1 counteracts tumor-driven immunosuppression, thereby enhancing the cytotoxic function of infiltrating T cells.

This combinatorial RNA approach leverages local pulmonary delivery to maximize therapeutic concentrations at the tumor site while minimizing systemic exposure and associated risks.

Methods and Experimental Design Insights

The research team engineered an LNP system capable of co-encapsulating both mRNA and siRNA, optimized for inhalation-mediated delivery. Key experimental features include:

• LNP formulation: Lipid nanoparticles were formulated to carry both mRNA (encoding anti-DDR1 scFv) and siPD-L1, ensuring stability and efficient uptake by pulmonary cells upon inhalation.
• In vitro validation: Pulmonary cancer cell lines were treated with the LNPs to confirm effective mRNA translation and PD-L1 gene silencing.
• In vivo models: Orthotopic and metastatic mouse models of lung cancer were employed to evaluate therapeutic efficacy, TME remodeling, and survival outcomes following inhaled administration of the RNA-loaded LNPs.
• Collagen architecture analysis: Post-treatment tumor tissues were examined using advanced imaging and biomechanical assays to quantify changes in collagen fiber alignment and tumor stiffness.

Protocol Parameters

• LNP preparation: Co-encapsulation of mRNA (anti-DDR1 scFv) and siRNA (siPD-L1) using optimized ionic and lipid ratios for pulmonary delivery.
• Dosing regimen: Inhalation delivery to mice, with dose intervals and concentrations titrated to maximize local lung exposure while minimizing systemic toxicity (see Hu et al., 2025 for detailed dosing).
• Assessment timeline: Collagen remodeling, T cell infiltration, and tumor regression were monitored at multiple time points post-inhalation to map both acute and sustained therapeutic effects.

Core Findings and Why They Matter

The dual RNA delivery strategy achieved several notable outcomes:

• Collagen Fiber Disruption: Expression of anti-DDR1 scFv in the tumor microenvironment led to disassembly and realignment of dense collagen fibers, directly reducing tumor stiffness and physical barriers to immune infiltration.
• Enhanced T Cell Infiltration: The modified ECM permitted greater T cell access to tumor cells, a critical factor for effective immunotherapy.
• PD-L1 Knockdown: siRNA-mediated silencing of PD-L1 relieved local immunosuppression, allowing infiltrating T cells to retain cytotoxic activity.
• Tumor Regression and Survival Benefit: In both orthotopic and metastatic models, inhalation of the mRNA/siRNA LNPs resulted in significant tumor shrinkage and extended overall survival, outperforming either monotherapy or control treatments (Hu et al., 2025).

These results demonstrate the feasibility and efficacy of targeting both physical and biochemical immune barriers via local RNA-based interventions, potentially informing future RNA translation mechanism research and mRNA vaccine development in oncology.

Comparison with Existing Internal Articles

Several internal articles have highlighted the pivotal role of chemically modified nucleotides, such as N1-Methyl-Pseudouridine-5'-Triphosphate (N1-Methylpseudo-UTP), in modern RNA workflows. For example, APExBIO’s thought-leadership overview discusses the use of N1-Methylpseudo-UTP to enhance RNA stability and translation in therapeutic settings, including inhaled RNA immunotherapy. Similarly, comparative analyses (internal review) underscore that the integration of modified nucleoside triphosphates into in vitro transcription with modified nucleotides produces RNA molecules with superior stability and reduced immunogenicity, both crucial for in vivo applications like those described in the reference study.

While the reference study does not specify the use of N1-Methylpseudo-UTP, the current consensus in RNA therapeutics research strongly favors such modifications to maximize RNA stability and translational efficiency (Kim et al., 2022). The synergy between advanced LNP delivery and optimized RNA chemistry is thus well-supported by both the primary and internal literature.

Limitations and Transferability

Despite its promising results, the strategy described by Hu et al. faces several limitations. Translation from murine models to human clinical contexts will require rigorous safety and efficacy profiling, particularly concerning immunogenicity, long-term RNA persistence, and potential off-target effects. The specificity of the inhaled delivery system to lung tissues is advantageous but may not be directly applicable to non-pulmonary solid tumors without further adaptation. Additionally, the study’s therapeutic efficacy depends on the success of in situ translation and gene silencing, both of which are influenced by the chemical properties of the RNA payload. Incorporating RNA stability enhancement strategies—such as the use of modified nucleotides—remains a crucial consideration for advancing these therapies toward clinical application.

Why this cross-domain matters, maturity, and limitations

The intersection of RNA delivery technologies, ECM modulation, and immunotherapy represents a significant cross-domain advance. The maturity of inhaled RNA therapeutics is rapidly increasing, but challenges remain in consistent manufacturing, scale-up, and regulatory approval. The approach described here is at the preclinical stage; further validation in non-human primates and early-phase human trials is essential before widespread adoption.

Research Support Resources

For researchers seeking to replicate or extend these findings, robust RNA synthesis protocols are essential. Chemically modified nucleotides such as N1-Methyl-Pseudouridine-5'-Triphosphate (SKU B8049) from APExBIO can be incorporated into in vitro transcription reactions to produce mRNAs with enhanced stability and translational efficiency, supporting advanced workflows in RNA translation mechanism research, mRNA vaccine development, and studies of the tumor microenvironment. This reagent is supplied at high purity and is suitable for workflows involving in vitro transcription with modified nucleotides and downstream therapeutic RNA applications.